Abion’s ABN501: A Promising Breakthrough in Targeted Anti-Cancer Therapy
Abion, led by CEO Shin Young-ki, has announced a significant breakthrough in the field of cancer research. The company’s groundbreaking anti-cancer drug, ABN501, has been selected as a potential candidate for the National Development Agency New Drugs’ research and development ecosystem. This recognition comes as a result of Abion’s tireless efforts to revolutionize cancer treatment. […]
